In Brief: Rehabilicare/Staodyn
This article was originally published in The Gray Sheet
Executive Summary
Rehabilicare/Staodyn: Electrotherapy device manufacturers agree to merge, forming an electromedical pain management and rehabilitation company with combined revenues of over $30 mil. Under the terms of a definitive agreement announced Dec. 2, New Brighton, Minnesota-based Rehabilicare would exchange 0.829 shares of Rehabilicare for each share of Staodyn common stock, valuing the deal at approximately $23 mil. based on Rehabilicare's Dec. 1 closing price of 4. The deal is expected to close in the first quarter of 1998...
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.